Vaxman I, et al. - In this retrospective cohort study, researchers assessed the performance of 18-Fluoro-2-deoxy-D-glucose positron emission tomography (^[18F] FDG-PET) with computed tomography (CT) (PET/CT) in the diagnostics and prognostication of newly diagnosed marginal zone lymphoma (MZL) patients. Between 2008 and 2016, patients at a single tertiary center who received immunotherapy, chemotherapy regimens, surgery or helicobacter pylori eradication for newly diagnosed MZL were included. Inclusion criteria included having a pre-treatment PET/CT (P-PET/CT). Review of P-PET/CT, interim (I-PET/CT) and end-of-treatment PET/CT (E-PET/CT) studies was performed. A total of 110 MZL patients (median age 67 years) who had P-PET/CT were examined. The median follow-up period was 63 months. The avidity of PET at baseline for the whole cohort, for MALT lymphoma, for NMZL and for SMZL were 70% (77/110 patients), 62.5% (40/64 patients), 76.4% (13/17 patients), and 82.7% (24/29 patients), respectively. Overall, above 70% of MZL were FDG avid. Positive E- PET/CT was identified as a strong prognostic factor for progression free survival.